PT  - JOURNAL ARTICLE
AU  - Wenhao Li
AU  - William Alazawi
TI  - Non-alcoholic fatty liver disease
AID  - 10.7861/clinmed.2020-0696
DP  - 2020 Sep 01
TA  - Clinical Medicine
PG  - 509--512
VI  - 20
IP  - 5
4099  - http://www.rcpjournals.org/content/20/5/509.short
4100  - http://www.rcpjournals.org/content/20/5/509.full
SO  - Clin Med2020 Sep 01; 20
AB  - Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. NAFLD is defined by excess fat in the liver and has a multidirectional relationship with metabolic syndrome. The prevalence of NAFLD has risen rapidly in recent years in line with the obesity epidemic and associated increases in type 2 diabetes, hypertension and hypercholesterolaemia. Patients with NAFLD are at risk of cardiovascular disease and cancer, and in a proportion of individuals, NAFLD is associated with liver damage. This article summarises the epidemiology of NAFLD, the clinical approach to risk-assessing patients and briefly outlines current and future management options.